GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Cyclically Adjusted Book per Share

Zevra Therapeutics (Zevra Therapeutics) Cyclically Adjusted Book per Share : $-29.39 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zevra Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $1.489. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-29.39 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-04-28), Zevra Therapeutics's current stock price is $4.52. Zevra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $-29.39. Zevra Therapeutics's Cyclically Adjusted PB Ratio of today is .


Zevra Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Zevra Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Cyclically Adjusted Book per Share Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -29.39

Zevra Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -31.31 -29.39

Competitive Comparison of Zevra Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Zevra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Cyclically Adjusted PB Ratio falls into.



Zevra Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zevra Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.489/129.4194*129.4194
=1.489

Current CPI (Dec. 2023) = 129.4194.

Zevra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -63.060 99.070 -82.378
201503 -70.657 99.621 -91.792
201506 3.894 100.684 5.005
201509 -6.455 100.392 -8.321
201512 -11.175 99.792 -14.493
201603 -12.671 100.470 -16.322
201606 0.364 101.688 0.463
201609 -10.707 101.861 -13.604
201612 -20.423 101.863 -25.948
201703 -37.063 102.862 -46.632
201706 -42.875 103.349 -53.690
201709 -52.506 104.136 -65.254
201712 -62.784 104.011 -78.121
201803 -84.405 105.290 -103.749
201806 -84.043 106.317 -102.306
201809 -95.095 106.507 -115.553
201812 -40.259 105.998 -49.155
201903 -42.799 107.251 -51.646
201906 -45.212 108.070 -54.144
201909 -34.888 108.329 -41.680
201912 -32.773 108.420 -39.121
202003 -19.359 108.902 -23.006
202006 -14.962 108.767 -17.803
202009 -13.752 109.815 -16.207
202012 -14.637 109.897 -17.237
202103 2.958 111.754 3.426
202106 3.736 114.631 4.218
202109 3.730 115.734 4.171
202112 3.631 117.630 3.995
202203 3.530 121.301 3.766
202206 2.877 125.017 2.978
202209 2.719 125.227 2.810
202212 2.175 125.222 2.248
202303 2.107 127.348 2.141
202306 2.019 128.729 2.030
202309 1.863 129.860 1.857
202312 1.489 129.419 1.489

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Zevra Therapeutics  (NAS:ZVRA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zevra Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (Zevra Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.
Executives
Neil F. Mcfarlane director, officer: President and CEO C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton officer: VP Fin & Corp Controller C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson director 215 FIRST STREET, CAMBRIDGE MA 02142
Joshua Schafer officer: CCO & EVP, Bus. Development SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
John B Bode director C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Watton Corey Michael director 22045 KAREN STREET, ELKHORN NE 68022
Douglas W Calder director 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon director
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni officer: VP, Corporate Controller C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle director, 10 percent owner, officer: President & CEO 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241